On the other hand, tumor cell autonomic factors, including oncogenic signaling pathways, mutational load, PD-L1 expression and downregulation of major histocompatibility complex (MHC) class I, inhibit the therapeutic of immunotherapy by modulating the TME [7, 8]. Here, CD274 is linked to neoplasm.